199 related articles for article (PubMed ID: 31948569)
1. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models.
Alghamri MS; Núñez FJ; Kamran N; Carney S; Altshuler D; Lowenstein PR; Castro MG
Methods Enzymol; 2020; 631():91-106. PubMed ID: 31948569
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
[TBL] [Abstract][Full Text] [Related]
5. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
[TBL] [Abstract][Full Text] [Related]
6. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():43-51. PubMed ID: 28720549
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
[TBL] [Abstract][Full Text] [Related]
8. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
King GD; Muhammad AK; Larocque D; Kelson KR; Xiong W; Liu C; Sanderson NS; Kroeger KM; Castro MG; Lowenstein PR
Mol Ther; 2011 Oct; 19(10):1793-801. PubMed ID: 21505426
[TBL] [Abstract][Full Text] [Related]
9. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.
Mineharu Y; Kamran N; Lowenstein PR; Castro MG
Mol Cancer Ther; 2014 Dec; 13(12):3024-36. PubMed ID: 25256739
[TBL] [Abstract][Full Text] [Related]
10. The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.
Lowenstein PR; Castro MG
Adv Pharmacol; 2016; 76():147-73. PubMed ID: 27288077
[TBL] [Abstract][Full Text] [Related]
11. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG
Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070
[TBL] [Abstract][Full Text] [Related]
12. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.
Ott M; Kassab C; Marisetty A; Hashimoto Y; Wei J; Zamler D; Leu JS; Tomaszowski KH; Sabbagh A; Fang D; Gupta P; Priebe W; Zielinski RJ; Burks JK; Long JP; Kong LY; Fuller GN; DeGroot J; Sulman EP; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(18):4983-4994. PubMed ID: 32605912
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
14. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
Curtin JF; Liu N; Candolfi M; Xiong W; Assi H; Yagiz K; Edwards MR; Michelsen KS; Kroeger KM; Liu C; Muhammad AK; Clark MC; Arditi M; Comin-Anduix B; Ribas A; Lowenstein PR; Castro MG
PLoS Med; 2009 Jan; 6(1):e10. PubMed ID: 19143470
[TBL] [Abstract][Full Text] [Related]
16. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
17. Antigen-receptor gene-modified T cells for treatment of glioma.
Ikeda H; Shiku H
Adv Exp Med Biol; 2012; 746():202-15. PubMed ID: 22639170
[TBL] [Abstract][Full Text] [Related]
18. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
Kim JE; Patel MA; Mangraviti A; Kim ES; Theodros D; Velarde E; Liu A; Sankey EW; Tam A; Xu H; Mathios D; Jackson CM; Harris-Bookman S; Garzon-Muvdi T; Sheu M; Martin AM; Tyler BM; Tran PT; Ye X; Olivi A; Taube JM; Burger PC; Drake CG; Brem H; Pardoll DM; Lim M
Clin Cancer Res; 2017 Jan; 23(1):124-136. PubMed ID: 27358487
[TBL] [Abstract][Full Text] [Related]
20. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
